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2Our initial research drive…
Limitations of traditional “speech
restructuring treatments”.
Carry-over of fluency from therapy to
daily living is often difficult and relapse is
common.
Speech, while initially stutter-free, is
often unnatural sounding.
3“A sense of invulnerability to
stuttering.”
Kalinowski (2003)












What are the optimal AAF parameters
that induce the greatest reduction in
stuttering frequency?
Armson & Stuart, 1998; Hargrave et al.,
1994; Kalinowski et al., 1993, 1995, 1996;
MacLeod et al., 1995; Stuart et al., 1996,
1997
7Do fluency effects of AAF generalize
from the lab to situations of daily living
and is speech natural?
Armson et al., 1997; Kalinowski et al.,
1999; Zimmerman et al., 1997
8Impetus For Device
Development
Effects are spontaneous without effort.
Speech is natural sounding.
Effects are seen in reading and
conversation.
Effects are evident monaurally
regardless of ear.






Does an in-the-ear device work?
With reading and monologue while over an
extended length of time.
Does the speech of the user sound
natural?
Is the user satisfied?
11
Initial Fitting and Follow-up
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Users’ Self Report Perspective
(Kalinowski et al., 2004)
A questionnaire was mailed to 250
individuals who purchased the fluency
device from three different
distribution centers in the US.
18
105 (42%) usable questionnaires from
85 males and 20 females were returned
from participants aged 7 – 81 (M = 32
years).
7-point scales assessed 6 indices on























The therapeutic effect and its
magnitude have been identified.
Phase 1 (Robey, 2006)
Explored the dimensions of the
therapeutic effect in preparations for
conducting a clinical trial.
Phase 2 (Robey, 2006)
Armson et al., 2006; Stuart et al., 2004, 2006
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Issues
(Ingham et al., 1998; Kalinowski, et al., 1998; Lincoln et al., 2006; Onslow, 2001)
Conversational speech?
Variability of responsiveness to AAF?
Children?
Combination with other therapy?
24
On the Issue of Variability
Are those individuals who stutter that
do not respond to AAF “silent
blockers?”
Is the duration of residual stuttering
episodes reduced during AAF?
That may explain why self reported















































Prolongations Repetitions Silent Blocks
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Questions
